BLOOMAGE BIOTECHNOLOGY CORP LTD Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
華 熙 生 物 科 技 有 限 公 司
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 00963) RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2015 FINANCIAL HIGHLIGHTSRevenue of the Group for the year ended 31 December 2015 was approximately RMB650,868,000, representing an increase of approximately RMB169,567,000 or 35.2% compared with the corresponding period in 2014.
Profit attributable to equity shareholders of the Company for the year ended 31 December 2015 was approximately RMB190,393,000, representing an increase of approximately RMB28,326,000 or 17.5% compared with the corresponding period in 2014.
The equity-settled share-based payment expenses, amortisation expenses of intangible assets and interest expenses on bank loans and convertible bonds of the Group were approximately RMB26,538,000 (2014: RMB26,549,000), RMB9,905,000 (2014: RMB220,000) and RMB8,202,000 (2014: RMB735,000) respectively in 2015, excluding the effect of the above expenses, the profit attributable to equity shareholders of the Company was approximately RMB235,038,000 (2014: RMB189,571,000).
The Board recommends a final dividend of HK$2.7 cents per share for the year ended 31 December 2015 (2014: HK$2.5 cents per share).
The board (the "Board") of directors (the "Directors") of Bloomage BioTechnology Corporation Limited (the "Company") is pleased to announce the audited consolidated results of the Company and its subsidiaries (collectively, the "Group") for the year ended 31 December 2015, together with comparative figures for the year ended 31 December 2014 as follows:
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME for the year ended 31 December 20152015 | 2014 | |||
Note | RMB'000 | RMB'000 | ||
Revenue | 4 | 650,868 | 481,301 | |
Cost of sales | (163,629) | (105,904) | ||
Gross profit | 487,239 | 375,397 | ||
Other revenue | 5 | 15,799 | 12,979 | |
Distribution costs | (107,070) | (74,646) | ||
Administrative expenses | (141,910) | (104,128) | ||
Other operating income/(expenses), net | 569 | (1,864) | ||
Profit from the operation | 254,627 | 207,738 | ||
Finance costs | 6(a) | (16,727) | (9,617) | |
Share of profits less losses of associates | 91 | - | ||
Share of loss of a joint venture | (66) | - | ||
Profit before taxation | 6 | 237,925 | 198,121 | |
Income tax | 7 | (47,530) | (36,055) | |
Profit for the year | 190,395 | 162,066 | ||
Other comprehensive income for the year (after tax adjustments): | ||||
Item that may be reclassified subsequently to profit or loss: | ||||
Exchange differences on translation of financial statements of foreign operations | (23) | 593 | ||
Share of other comprehensive income of equity-accounted investees | 5,841 | - | ||
Total comprehensive income for the year | 196,213 | 162,659 | ||
Profit attributable to: | ||||
Equity shareholders of the Company | 190,393 | 162,067 | ||
Non-controlling interests | 2 | (1) | ||
Profit for the year | 190,395 | 162,066 | ||
Total comprehensive income attributable to: | ||||
Equity shareholders of the Company | 196,211 | 162,667 | ||
Non-controlling interests | 2 | (8) | ||
Total comprehensive income for the year | 196,213 | 162,659 | ||
Earnings per share (RMB) | ||||
Basic | 8(a) | 0.565 | 0.488 | |
Diluted | 8(b) | 0.553 | 0.473 | |
2015 | 2014 | |||
Note | RMB'000 | RMB'000 | ||
Non-current assets | ||||
Property, plant and equipment, net | 9 | 362,731 | 375,622 | |
Construction in progress | 5,383 | 412 | ||
Intangible assets | 10 | 208,093 | 1,160 | |
Lease prepayments | 59,161 | 60,470 | ||
Interest in associates | 11 | 240,949 | - | |
Interest in a joint venture | - | - | ||
Deferred tax assets | 11,615 | 11,383 | ||
Other non-current assets | 35,723 | - | ||
Total non-current assets | 923,655 | 449,047 | ||
Current assets | ||||
Inventories | 117,592 | 55,082 | ||
Trade and other receivables | 12 | 251,874 | 177,672 | |
Available-for-sale financial assets | 13 | - | 80,000 | |
Restricted cash | 14 | 255,000 | 15,803 | |
Cash and cash equivalents | 651,050 | 187,840 | ||
Total current assets | 1,275,516 | 516,397 | ||
Current liabilities | ||||
Secured bank loans | 14 | 472,873 | - | |
Trade and other payables | 15 | 117,801 | 136,577 | |
Current portion of preferred shares | 11,538 | 10,683 | ||
Income tax payable | 21,888 | 13,394 | ||
Total current liabilities | 624,100 | 160,654 | ||
Net current assets | 651,416 | 355,743 | ||
Total assets less current liabilities | 1,575,071 | 804,790 | ||
Non-current liabilities | ||||
Preferred shares | 39,933 | 42,946 | ||
Convertible bonds | 16 | 326,938 | - | |
Deferred income | 16,243 | 9,337 | ||
Total non-current liabilities | 383,114 | 52,283 | ||
NET ASSETS | 1,191,957 | 752,507 | ||
2015 | 2014 | ||
RMB'000 | RMB'000 | ||
CAPITAL AND RESERVES | |||
Share capital | 3,117 | 2,969 | |
Reserves | 1,188,787 | 749,487 | |
Total equity attributable to equity shareholders of the Company | 1,191,904 | 752,456 | |
Non-controlling interests | 53 | 51 | |
TOTAL EQUITY | 1,191,957 | 752,507 | |
Bloomage BioTechnology Corporation Ltd. issued this content on 22 March 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 22 March 2016 12:53:13 UTC
Original Document: http://www.bloomagebio-tech.com/attachment/2016032220320100002460283_en.pdf
